BLRX News and Press, BioLineRx Ltd. From 01/22/21

BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter PR Newswire TEL AVIV, Israel , Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical c...

Gainers: Obalon Therapeutics (OBLN) +438%.Caladrius Biosciences (CLBS) +121%.Adamis Pharmaceuticals (ADMP) +72%.Steel Connect (STCN) +54%.Titan Medical (TMDI) +52%.Tiziana Life Sciences (TLSA) +50%.Iterum Therapeutics (ITRM) +40%.Dare Bioscience (DARE) +33%.17 Education & T...

Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study for HST-003.AcelRx P...

Due to demand, BioLineRx's (BLRX) underwriter, H.C. Wainwright & Co. has agreed to increase the size of the previous offering and purchase 12.5M ADSs (from 4.17M) at $2.40/ADS. Each ADS represents 15 ordinary shares.Expected gross proceeds are ~$30M. Underwriter's over-allotment is a...

BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million PR Newswire TEL AVIV, Israel , Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announ...

BioLineRx (BLRX) has agreed to purchase on a firm commitment basis 4.17M ADSs of the company, at a price to the public of $2.40 per ADS, less underwriting discounts and commissions.Offering is expected to occur on or about January 22, 2021.Gross proceeds are expected to be $10M.Comp...

BioLineRx Announces $10 Million Bought Deal Offering PR Newswire TEL AVIV, Israel , Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered ...

Today, the focus is on tech and growth stocks. 2020 was a bull year for tech and growth. Our contributors discuss where they believe more opportunities lie ahead for 2021 and beyond. Thank you for your continued reading and engagement - we end the 2021 Roundtable series tomorrow w...

3 Biotech Penny Stocks to Watch This Month As we head toward the middle of January, there are plenty of penny stocks that are showing potential. This week got off to an interesting start, with most blue-chip stocks trading lower. However, as the day progressed we watched many stocks...

H.C. Wainwright points out that BioLineRx ([[BLRX]] -16.3%) shares selloff following positive data from COMBAT study, is a "classic example of 'sell on the news' following a strong stock run up. Over one year shares have gained ~52% while YTD shares have increased ...